Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.
Keros Therapeutics stock last closed at $13.89, down 2.87% from the previous day, and has decreased 75.1% in one year. It has overperformed other stocks in the Biotechnology industry by 0.02 percentage points. Keros Therapeutics stock is currently +52.3% from its 52-week low of $9.12, and -80.81% from its 52-week high of $72.37.
At the moment, there are 40.56M KROS shares outstanding. The market cap of KROS is $563.41M. In the last 24 hours, 869,972 KROS shares were traded.
How to Buy Keros Therapeutics Stock
Wondering how to invest in Keros Therapeutics stock? Here's how.
Figure out where to buy Keros Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Keros Therapeutics stock.
Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit funds into your investment account: Pick your method of payment and add your information.
Research Keros Therapeutics stock: The Keros Therapeutics ticker symbol is KROS. Is Keros Therapeutics stock a good investment? Should you buy shares of KROS? How do KROS's underlying business fundamentals look? Do top analysts think Keros Therapeutics is a good buy? Why has KROS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if KROS is a good stock to buy).
Place your KROS purchase: Decide if you will purchase KROS shares at the current market price or use a limit order to buy KROS stock at a particular price.
Monitor your investment in KROS: Create a watchlist to important notifications about your investment in Keros Therapeutics stock.
Step 1: Figure out where to buy Keros Therapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy KROS shares.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world financial markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you are able to invest in KROS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Keros Therapeutics stock
Once you have figured out the best place to buy Keros Therapeutics stock, it's very important to research their stock before you buy, so you actually wrap your head around the risk as well as the upside.
Keros Therapeutics shares quick numbers
KROS Price
$13.89
1w %
6.11%
1y %
-75.1%
5y %
-51.4%
P/E
-2.78x
P/B
0.99x
P/S
146.21x
PEG
N/A
Revenue
$3.55M
Earnings
-$187.35M
Fore. Rev. Growth
112.37%
Fore. Earn. Growth
N/A
Market Cap
$563.41M
Next Earnings
May 6, 2025
Next Dividend
N/A
Keros Therapeutics Due Diligence Score
WallStreetZen was built to help average investors perform more accurate fundamental analysis in minutes instead of hours.
Total KROS debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than short-term liabilities on the KROS balance sheet.
KROS has cash burn of 162800000. It has sufficient cash and short-term investments to cover this for at least one year.
KROS has $561.38M in cash and short term investments. This is enough to cover its annual cash burn of $162.80M.
KROS has a low debt to equity ratio of 0.08.
There are more short-term assets than long-term liabilities on the KROS balance sheet.
Signs that KROS is not financially healthy:
KROS profit margin has gone up by 960.42 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy KROS stock
Out of 8 Equities analysts who give recommendations on KROS, the consensus analyst rating on Keros Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent KROS Analyst Forecasts
Andreas Argyrides, a top 5% analyst from Wedbush downgrades KROS to a hold rating and lowers their KROS price target from $47.00 to $15.00, on Jan 17, 2025.
Greg Harrison, a bottom 18% analyst from ScotiaBank maintains KROS with a buy rating and lowers their KROS price target from $44.00 to $41.00, on Jan 16, 2025.
Vamil Divan, a top 4% analyst from Guggenheim maintains KROS with a strong buy rating and raises their KROS price target from $96.00 to $102.00, on Dec 5, 2024.
Last year, KROS revenue was $3.55M. During the past 5 year, KROS's revenue has gone up by -18.71% per year. This was slower than the Biotechnology industry average of 44.4%.
No, Keros Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about KROS
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your KROS purchase
There are two main types of orders:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are generally the easiest way to buy.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at an exact dollar amount, use a limit order.
Press the Open button and eToro will execute your order.
If you want additional help with buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Keros Therapeutics share?
As of Apr 22, 2025, it costs $13.89 to buy one share of Keros Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $6, you can buy 0.432 shares of KROS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.